Key points are not available for this paper at this time.
The real-world therapeutic effect of pembrolizumab for R/M SCCHN was comparable to that observed in the KEYNOTE048 trial. In addition, irAEs and best overall response were considered as prognostic factors.
Okada et al. (Mon,) studied this question.